About: Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises
Creator	Rezaei, Nima Saghazadeh, Amene Basiri, Arefeh Beheshtizadeh, Nima Hoseinpour, Mahdieh Pazhouhnia, Zahra
Source	Medline; PMC
abstract	Novel coronavirus disease (COVID-19) has attracted much attention around the world due to its rapid transmission among humans and relatively high mortality rate. Studies are increasing to find the best therapeutic approach for the disease and its management. Regenerative medicine offers various cell-tissue therapeutics and related products, such as stem cell therapy, natural killer (NK) cell therapy, Chimeric antigen receptor (CAR) T cell therapy, exosomes, and tissue products. Interestingly, mesenchymal stem cells (MSCs) can reduce inflammatory symptoms and protect against cytokine storm, which critically contributes to the COVID-19 progression. Notably, having the potentials to exert cytotoxic effects on infected cells and induce interferon production probably make NK cells a candidate for COVID-19 cell therapy. Besides, exosomes are one of the crucial products of cells that can exert therapeutic effects through the induction of immune responses and neutralizing antibody titers. The paper aims to briefly consider current options for COVID-19 therapy to show that there is no specific cure for COVID-19, and then assess the real opportunities and range of promises regenerative medicine can provide for specific treatment of COVID-19. [Figure: see text]
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1007/s12015-020-09994-5
bibo:pmid	32564256
has license	no-cc
sha1sum (hex)	66c315a9cc1501d017b9c56989a79257799b16b7
schema:url	https://doi.org/10.1007/s12015-020-09994-5
resource representing a document's title	Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises
has PubMed Central identifier	PMC7305935
has PubMed identifier	32564256
schema:publication	Stem Cell Rev Rep
resource representing a document's body	covid:66c315a9cc1501d017b9c56989a79257799b16b7#body_text
is schema:about of	named entity 'aims' named entity 'cell therapy' named entity 'exosomes' named entity 'immune responses' named entity 'therapy' named entity 'reduce' named entity 'Real' named entity 'PROGRESSION' covid:arg/66c315a9cc1501d017b9c56989a79257799b16b7 named entity 'high' named entity 'therapy' named entity 'current' named entity 'products' named entity 'inflammatory' named entity 'tissue' named entity 'neutralizing antibody' named entity 'opportunities' named entity 'exosomes' named entity 'therapy' named entity 'Promises' named entity 'cell therapy' named entity 'natural killer (NK) cell' named entity 'COVID-19' named entity 'exosomes' named entity 'COVID' named entity 'regenerative medicine' named entity 'neutralizing antibody' named entity 'COVID-19' named entity 'stem cell' named entity 'acute lung injury' named entity 'SARS-CoV' named entity 'MSCs' named entity 'therapeutic effects' named entity 'chemical compounds' named entity 'COVID' named entity 'cytokines' named entity 'immune regulation' named entity 'dendritic cells' named entity 'cytokine storm' named entity 'high levels' named entity 'organoid' named entity 'passive transfer' named entity 'Stem cells' named entity 'exosomes' named entity 'influenza virus' named entity 'United States' named entity 'MSCs' named entity 'inflammation' named entity 'antibody therapy' named entity 'mesenchymal stem cells' named entity 'SARS-CoV' named entity 'cell-based' named entity 'bead' named entity 'clinical trials' named entity 'COVID-19' named entity 'structural proteins' named entity 'tissue culture' named entity 'G-CSF' named entity 'life-threatening' named entity 'immunomodulatory' named entity 'antibodies' named entity 'MSCs' named entity 'ACE2' named entity 'COVID-19' named entity 'BSL-2' named entity 'coronavirus' named entity 'high-throughput' named entity 'ClinicalTrials.gov' named entity 'Regenerative medicine' named entity 'acute lung injury' named entity 'COVID' named entity 'bacteria' named entity 'generated directly' named entity 'anti-viral' named entity 'COVID-19' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software